

# Center of Excellence Application - Test 2022

## Application details

Center name	Test 2022
Scope	GEP NET, PULM NET
Submitted	14 December 2022
Submitted by	Test Member

## Administrative contact

Company / Institution	a
Contact person	a
VAT Number	a
Invoice address	a

## 1. Structure (as in 2021)

### Named GEP NET Specialists

Position	Responsible expert
1st GEP NET Specialist	a a
2nd GEP NET Specialist	a a
More GEP NET Specialists	a

### Named PULM NET Specialists

Position	Responsible expert
1st PULM NET Specialist	a a
2nd PULM NET Specialist	a a
More PULM NET Specialists	a

### 1.1 Organizational Chart/ Management Structure

Position	Responsible expert
1.1.1 Head of the Center	a a
1.1.2 Center coordination	a a
1.1.3 Contact partner for all practitioners	a a
1.1.4 Patient coordinator	a a
1.1.5 Quality management coordinator	a a

## 1.2 Main Partners / core partners

Position	Responsible expert
1.2.1 Gastroenterology	a a
1.2.2 Endocrinology	a a
1.2.3 Oncology	a a
1.2.4 Pathology	a a
1.2.5 Radiology	a a
1.2.6 Nuclear Medicine	a a
1.2.7 Visceral Surgery	a a
1.2.8 Endocrine Surgery	a a
1.2.9 Thoracic surgeon	a a
1.2.10 Pulmonologist	a a

## 1.3 Secondary Partners

Position	Responsible expert
1.3.1 Laboratory (accredited)	a a
1.3.2 Genetics (accredited laboratory)	a a
1.3.3 Cardiology	a a
1.3.4 Cardiac Surgery	a a
1.3.6 Transplant Surgery	a a
1.3.7 Radiotherapy	a a
1.3.8 Palliative care	a a
1.3.9 Pain Therapy	a a

## 1.4 Supportive Care Partners

Position	Responsible expert
1.4.1 Psychosocial support offers	a a
1.4.2 Nutrition expert	a a
1.4.3 Self-help-group	a a

## 1.5 Referring Partners / Affiliated Partners

Position	Responsible expert
1.5.1 University hospitals	a a
1.5.2 Non-university hospitals	a a
1.5.3 Physicians in private practice	a a

## 2. Interdisciplinary Cooperation and Communication Structure (as in 2021)

### 2.1. NET Tumor Board / Multidisciplinary Decision Making Team (MDT)

Position	Statement
2.1.1 Participants	n/a
2.1.2.5 Frequency of Tumorboard meetings	n/a

## 3. Specialist GEP NET Consultation (as in 2021)

### 3.1 Resources

Position	Statement
3.1.4 Number of NET specialists	Number: n/a
SOP description	n/a

## 4. Endocrinology (as in 2021)

### 4.1 Resources

Position	Statement
4.1.2 Number of endocrinologists	Number: n/a
SOP description	n/a

## 5. Gastroenterology (as in 2021)

### 5.1. Resources

Position	Statement
5.1.2 Number of gastroenterologists	Number: n/a
5.1.5 Number of specialist endoscopists	Number: n/a
5.1.6 Equipment	n/a
SOP description	n/a

## 6. Oncology (as in 2021)

### 6.1. Resources

Position	Statement
6.1.2 Number of oncologists	Number: n/a

## 6.1. Resources

SOP description	n/a
-----------------	-----

## 7. Pathology (as in 2021)

### 7.1 Resources

Position	Statement
7.3.1 Number of pathologists	Number: n/a
7.3.6 Number of pathologists in PULM	Number: n/a
SOP description	n/a

## 8. Radiology (as in 2021)

### 8.1 Resources

Position	Statement
8.1.2 Number of radiologists	Number: n/a
SOP description	n/a

## 9. Nuclear Medicine (as in 2021)

### 9.1 Resources

Position	Statement
9.1.2 Number of nuclear medicine experts	Number: n/a
9.1.4 Equipment	n/a
SOP description	n/a

## 10. Surgery (as in 2021)

### 10.1. Resources

Position	Statement
10.1.2 Number of HBP surgeons	Number: n/a
10.1.3 Number of thoracic surgeons	Number: n/a
Hepato-bilio-pancreatic surgeon as liaison service?	Answer: No
Thoracic surgeon as liaison service?	Answer: No

## 11. Pulmonology (as in 2021)

### 11.1 Resources

Position	Statement
11.1.2 Number of pulmonologist	Number: n/a
11.1.4 Number of specialist endoscopists	Number: n/a
SOP description	n/a

## 12. Scientific Activities (as in 2021)

### 12.1 GEP NET Research Group

Position	Statement
Dedicated GEP NET research group	No

## 13. Patient Involvement (as in 2021)

### 13. Patient Involvement

Position	Statement
13.1 How are your patients informed/involved?	n/a
13.2 Patient feedback	n/a

## 14. Follow-up and tumor documentation (as in 2021)

### 14. Follow-up and Tumor Documentation

Position	Statement
Registry - how is your patient registry organized?	n/a
Do you use electronic files?	n/a
How is the follow-up organized?	n/a

## 15. Key Figures 2021

### 15.1 NET Patients

Position	Statement
15.1.1 Number of <b>new</b> GEP NET patients	Number: 1212
15.1.2 New GEP NET patients treated in center	Number: 1212 Percentage: n/a
15.1.3 Number of current GEP NET patients	Number: 1212
15.1.4 Number of <b>new</b> PULM NET patients	Number: n/a
15.1.5 New PULM NET patients treated in center	Number: n/a Percentage: n/a
15.1.6 Number of current PULM NET patients	Number: 1212

### 15.2 NET Tumor board / Multidisciplinary Decision Making Team (MDT)

Position	Statement
15.2.1 GEP NET patients discussed in tumor board	Number of patients: 1212 Number of discussions: 1212
15.2.2 Number of <b>new</b> GEP NET patients discussed in tumor board	Number: 1212
15.2.3 Number of second opinions	Number: n/a
15.2.4 <b>PULM NET patients discussed in tumor board</b>	Number of patients: 1212 Number of discussions: 1212

## 15.2 NET Tumor board / Multidisciplinary Decision Making Team (MDT)

15.2.5 Number of <b>new</b> PULM NET patients discussed in tumor board	Number: 1212
15.2.6 Number of second opinions on PULM NET patients	Number: n/a
15.2.7 Treatment decision making (outcome of the tumor board)	Surgery: Interventional radiology: Nuclear medicine: Medical therapies: Watch and wait: Others: Adherence to ENETS guidelines: n/a Sample size: n/a
15.2.8 Adherence to MDT decision making	Percentage: n/a Sample size: n/a

## 15.3 Specialist NET Consultation

Position	Statement
15.3.1 Waiting times	Waiting times consultation appointment (days): n/a Period during which staging is concluded (days): n/a

## 15.6 Oncology

Position	Statement
15.6.1 Number of NETS with systemic and targeted therapy (somatostatin therapy is excluded)	Interferon: n/a Everolimus: n/a Sunitinib: n/a Other: n/a Streptozocin/5-FU: n/a Temozolomide/Capecitabine: n/a Carbo- or Cisplatin/Etoposide: n/a Other combinations: n/a
15.6.2 Number of serious events	Targeted therapy: Systemic therapy: Interferon therapy:
15.6.3 Number of deaths	Targeted therapy: Systemic therapy: Interferon therapy:
15.6.4 Number of PULM NETS with systemic and targeted therapy (somatostatin therapy is excluded)	Interferon: n/a Everolimus: n/a Sunitinib: n/a Other: n/a Streptozocin/5-FU: n/a Temozolomide/Capecitabine: n/a Carbo- or Cisplatin/Etoposide: n/a Other combinations: n/a
15.6.5 Number of serious adverse events in PULM NET	Targeted therapy: Systemic therapy: Interferon therapy:
15.6.6 Number of deaths in PULM NET	Targeted therapy: Systemic therapy: Interferon therapy:

## 15.7 Pathology

Position	Statement
15.7.2 Reports on biopsies in GEP NET	Number: n/a
15.7.3 Reports on surgical specimen in GEP NET	Number: n/a

## 15.7 Pathology

15.7.4 Immunohistochemical examinations in GEP NET	Number: n/a
15.7.5 Percentage of complete reports in GEP NET	Percentage: n/a
15.7.7 Reports on biopsies in PULM NET	Number: n/a
15.7.8 Reports on surgical specimen in PULM NET	Number: n/a
15.7.9 Immunohistochemical examinations in PULM NET	Number: n/a
15.7.10 Percentage of complete reports in PULM NET	Percentage: n/a

## 15.8 Radiology

Position	Statement
15.8.2 TA(C)E	Number of TA(C)E in NET: n/a Number of ablation in NET: n/a
15.8.3 SIRT/intra-arterial PRRT with (radio) pharmaceuticals	SIRT in NET: n/a
15.8.7 Morbidity in (combined) interventional radiology	Timeframe: In house Source: Random sample Number of serious adverse events: 1212 (1212.0%)
15.8.8 Mortality in (combined) interventional radiology	Timeframe: In house Source: Random sample Number of deaths: 1212 (1212.0%)

## 15.9 Nuclear Medicine

Position	Statement
15.9.1 Number of SSTR PET in NET	Number: 1212
15.9.2 Number of FDG PET in NET	Number: n/a
15.9.4 Therapeutic interventions in own center	All in own center: 1212 PRRT: n/a MIBG: n/a PRRT in combination with other treatments: n/a
15.9.5 Therapeutic interventions in partner centers	All in partner center: n/a PRRT: n/a MIBG: n/a PRRT in combination with other treatments: n/a
15.9.6 Morbidity after therapeutic interventions	Timeframe: n/a Source: n/a Number of serious adverse events after PRRT: Number of serious adverse events after MIBG: Number of serious adverse events after PRRT in combination with other treatments:
15.9.7 Mortality after therapeutic interventions	Timeframe: n/a Source: n/a Number of deaths after PRRT: Number of deaths after MIBG: Number of deaths after PRRT in combination with other treatments:

## 15.10 Surgery

Position	Statement
15.10.1 Number of hepato-biliary surgeries	Partial hepatectomies: n/a Radiofrequency assisted resection: n/a Other: n/a

## 15.10 Surgery

15.10.2 Number of hepato-biliary surgeries in GEP NET	Partial hepatectomies: n/a Radiofrequency assisted resection: n/a Other: n/a
15.10.3 Number of pancreatic surgeries	Pancreaticoduodenectomy: n/a Distal resection: n/a Enucleation: n/a Other: n/a
15.10.4 Number of pancreatic surgeries in GEP NET	Pancreaticoduodenectomy: n/a Distal resection: n/a Enucleation: n/a Other: n/a
15.10.5 Number of bowel surgery in general	Stomach: n/a Ileum: n/a Colon: n/a Rectum: n/a Peritoneal resections: n/a Other: n/a
15.10.6 Number of bowel surgery in NET patients	Stomach: n/a Ileum: n/a Colon: n/a Rectum: n/a Peritoneal resections: n/a Other: n/a
15.10.7 Morbidity and mortality after hepato-biliary surgery in NET patients Index procedure : partial hepatectomy in NET	Timeframe: In house Source: Random sample Grade 3: Grade 4: Grade 5: 255 (255.0%)
15.10.8 Morbidity and mortality after pancreatic surgery in NET patients Index procedure: pancreaticoduodenectomy in NET	Timeframe: 30 days Source: Random sample Grade 3: Grade 4: Grade 5:
15.10.9 Morbidity and mortality after bowel surgery in NET patients Index procedure: SI NET SURGERY	Timeframe: In house Source: All Grade 3: Grade 4: Grade 5:
15.10.10 Number of thoracic surgeries in NET and non-NET patients	Anatomical lung resections: n/a Atypical lung resections: n/a Minimal invasive (video assisted) lung resections (VATS): n/a
15.10.11 Number of thoracic surgeries in Pulm NET	Anatomical lung resections: n/a Atypical lung resections: n/a Minimal invasive (video assisted) lung resections (VATS): n/a
15.10.12 Morbidity and mortality after thoracic surgery in NET patients Index procedure: Anatomical lung resections	Timeframe: n/a Source: n/a Grade 3: Grade 4: Grade 5:

## 15.12 Scientific activities

Position	Statement
15.12.1 Clinical trials	Prospective trials: 12 NET patients in clinical trials: 12 New NET patients in clinical trials: 1212
15.12.2 Publications	Original articles: 121 Other peer reviewed publications: 12

## 15.12 Scientific activities

15.12.3 Research projects	International studies: n/a Retrospective analysis: n/a Basic NET research: n/a Research students (PhD): n/a Research students (Lower grade): n/a International exchange of experience: n/a
---------------------------	---

## 15.13 Patient Questionnaire

Position	Statement
15.13.1 Percentage of patient questionnaire feedback	Percentage: n/a

## 15.14 F / U data

Position	Statement
15.14.1 GEP NET patients in follow up	Number of GEP NET patients: 1212 Percentage of GEP NET patients: n/a
15.14.2 GEP NET patients lost to follow up	Percentage of GEP NET patients lost: n/a
15.14.3 <b>PULM NET patients in follow up</b>	Number of PULM NET patients: 121 Percentage of PULM NET patients: n/a
15.14.2 GEP NET patients lost to follow up	Percentage of PULM NET patients lost: n/a